首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer research

缩写:CANCER RES

ISSN:0008-5472

e-ISSN:1538-7445

IF/分区:22.6/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引12921条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Yuelei Zhang,Bin Yang,Xin Hou et al. Yuelei Zhang et al.
High-grade serous ovarian cancer (HGSOC) is a lethal malignancy characterized by profound intratumoral heterogeneity and immune evasion. While previous research has identified four molecular subtypes of HGSOC, defining their spatial distrib...
Justin Powers,Lai Wei,Justin Chak Ting Cheung et al. Justin Powers et al.
The lethality of pancreatic ductal adenocarcinoma (PDAC) is driven in part by cellular plasticity that facilitates dedifferentiation and dissemination. Although transcriptional programs underlying these processes are well characterized, the...
Shengbo Han,Guozheng Lv,Ping Hu et al. Shengbo Han et al.
Fusobacterium nucleatum (F. nucleatum) is a key microbial driver of colorectal cancer (CRC) progression. Here, we identified an intercellular signaling axis through which F. nucleatum remodels the immune microenvironment. Analysis of 54 cli...
Jianfeng Yu,Jieru Zhang,Jun Zhang et al. Jianfeng Yu et al.
Although non-small cell lung cancer (NSCLC) is among the most prevalent malignancies, currently available treatments remain largely ineffective, highlighting the need to elucidate the precise mechanisms of tumorigenesis. The Mpr1/Pad1 N-ter...
Alberto Martín,Inés M García-Pérez,Sonia San José et al. Alberto Martín et al.
Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses are often hampered by the rapid resistance onset. Proteolysis-targeting chimeras (PROTACs) have ...
Jeffrey West,Bina Desai,Maximilian A R Strobl et al. Jeffrey West et al.
A population of cells within a tumor can be described as antifragile (the opposite of fragile) if they derive a benefit from fluctuations or perturbations in environmental conditions induced by treatment. Treatment fluctuations could either...
Mona Foth,Wontak Kim,Kayla O&#x;Toole et al. Mona Foth et al.
Most patients with advanced BRAF or NRAS-driven melanoma receive front-line immunotherapy. However, if immunotherapy fails, BRAF-mutated patients have effective second-line therapies, whereas NRAS-mutated patients lack pathway-targeted opti...
Alexandra Backlund,Catherine H Samaniego,Rashika Rangaraj et al. Alexandra Backlund et al.
The influence of genetic ancestry on cancer development and treatment response is underappreciated within pediatric neuro-oncology. Pediatric brain tumors (PBTs) comprise the deadliest malignancies among childhood cancers. Poorer prognoses ...
Melanie S Flint,David M O&#x;Malley,Domenica Lorusso et al. Melanie S Flint et al.
Glucocorticoid receptor (GR) signaling is critical to our physiology but is dysregulated in cancer by the pain, psychological distress, iatrogenic morbidity, and pathology associated with an advanced, invasive disease. Many tumors exploit g...
Justin D Clubb,Ryan M Shih,Torahito A Gao et al. Justin D Clubb et al.
Chimeric-antigen receptor (CAR)-T cell therapy has shown early promise against glioblastoma, which lacks effective treatment options. However, two key challenges curtail efficacy: tumor-antigen heterogeneity and an immunosuppressive tumor m...